Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio

Prostate

Volumn 68, Issue 15, 2008, Pages 1624-1634

  Reagan Shaw, Shannon ^a   Nihal, Minakshi ^a,b   Ahsan, Haseeb ^a   Mukhtar, Hasan ^a,b   Ahmad, Nihal ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Apoptosis; Prostate cancer; SELECT; Selenium; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; SELENIUM; SHORT HAIRPIN RNA; CYCLINE; PROSTATE SPECIFIC ANTIGEN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; CELL CYCLE; CELL SURVIVAL; DOWN REGULATION; DRUG POTENTIATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; MALE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SELENIUM; UP-REGULATION; VITAMIN E;

EID: 55249099408     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20824     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-2040.
3. Ries L, Melbert D, Krapcho M, Mariotto A, Miller B, Feuer E, Clegg L, Horner M, Howlader N, Eisner M, Reichman M, Edwards B, editors. SEER Cancer Statistics Review 1975-2004. Bethesda, MD: National Cancer Institute; 2004.
4. Mukhtar H, Ahmad N. Cancer chemoprevention: Future holds in multiple agents. Toxicol Appl Pharmacol 1999;158:207-210.
5. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-2505.
6. Ahmad N, Mukhtar H. Green tea polyphenols and cancer: Biologic mechanisms and practical implications. Nutr Rev 1999;57:78-83.
7. Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: Implications for chemoprevention. Prostate 2007;67:582-590.
8. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethyl-lated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-2886.
9. Venkateswaran V, Fleshner NE, Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2004;7:54-56.
10. Morris VC, Levander OA. Selenium content of foods. J Nutr 1970;100:1383-1388.
11. Schrauzer GN. Nutritional selenium supplements: Product types, quality, and safety. J Am Coll Nutr 2001;20:1-4.
12. Harris PL, Quaife ML, Swanson WJ. Vitamin E content of foods. J Nutr 1950;40:367-381.
13. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94-102.
14. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-446.
15. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Estaquio C, Hercberg S. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.-MAX trial. Int J Cancer 2005;116:182-186.
16. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:23-33.
17. Rodriguez C, Jacobs EJ, Mondul AM, Calle EE, McCullough ML, Thun MJ. Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 2004;13:378-382.
18. The HOPE and HOPE-TOO Trial Investigators. Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial. JAMA 2005;293:1338-1347.
19. Wright ME, Weinstein SJ, Lawson KA, Albanes D, Subar AF, Dixon LB, Mouw T, Schatzkin A, Leitzmann MF. Supplemental and dietary vitamin e intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2007;16:1128-1135.
20. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-734.
21. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-1224.
22. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP. Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 2006;42:2463-2471.
23. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 2001;61:7071-7078.
24. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 1985;130:603-609.
25. Zhao R, Domann FE, Zhong W. Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol Cancer Ther 2006;5:3275-3284.
26. Sigounas G, Anagnostou A, Sterner M. dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 1997;28:30-35.
27. Zhang M, Altuwaijri S, Yeh S. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004;23:3080-3088.
28. Zu K, Hawthorn L, Ip C. Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells. Mol Cancer Ther 2005;4:43-50.
29. Zhang H, Wu Y, Malewicz B, Lu J, Li S, Marshall J, Ip C, Dong Y. Augmented suppression of androgen receptor signaling by a combination of alpha-tocopheryl succinate and methylseleninic acid. Cancer 2006;107:2942-2948.
30. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003;63:6988-6995.
31. Prasad KN, Kumar B, Yan XD, Hanson AJ, Cole WC. |alpha|-tocopheryl succinate, the most effective form of Vitamin E for adjuvant cancer treatment: A review. J Am Coll Nutr 2003;22: 108-117.
32. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethyl-lated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-2886.
33. Reagan-Shaw S, Ahmad N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res 2006;66:1062-1069.
34. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003;63:52-59.
35. Malafa M, Fokum F, Andoh J, Neitzel L, Bandyopadhyay S, Zhan R, Iiizumi M, Furuta E, Horvath E, Watabe K. Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis. Int J Cancer 2006;118:2441-2447.
36. Shiau CW, Huang JW, Wang DS, Weng JR, Yang CC, Lin CH, Li C, Chen CS. alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. J Biol Chem 2006;281:11819-11825.
37. Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci 2002;99:7408-7413.
38. Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003;300:357-363.
39. Venkateswaran V, Fleshner NE, Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2004;7:54-56.
40. Jiang C, Wang Z, Ganther H, Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002;1:1059-1066.
41. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl 2005;216:64-81.
42. Danial NN. BCL-2 family proteins: Critical checkpoints of apoptotic cell death. Clin Cancer Res 2007;13:7254-7263.
43. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998;52: 1085-1090.
44. Sabichi AL, Lee JJ, Taylor RJ, Thompson PM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of 1-selenomethionine: A Southwest Oncology Group Study. Clin Cancer Res 2006;12:2178-2184.
45. Traber MG. Utilization of vitamin E. Biofactors 1999;10:115-120.
46. Zu K, Hawthorn L, Ip C. Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells. Mol Cancer Ther 2005;4:43-50.
47. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, Kolenko VM. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005;24:5868-5877.
48. Hu H, Jiang C, Ip C, Rustum YM, Lu J. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005;11:2379-2388.
49. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001;20:7342-7351.
50. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernandez PL, Albanell J. Activation of nuclear f actor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005;93:1285-1294.
51. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-4197.
52. Gasparian AV, Yao YJ, Lu J, Yemelyanov AY, Lyakh LA, Slaga TJ, Budunova IV. Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 2002;l:1079-1087.
53. Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: Implications for chemoprevention. Prostate 2007;67:582-590.